ToxSci Advance Access originally published online on November 17, 2004
Toxicological Sciences 2005 83(2):246-256; doi:10.1093/toxsci/kfi040
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Toxicological Sciences vol. 83 no. 2 © Society of Toxicology 2005; all rights reserved.
Deregulation of Cell Proliferation by Polycyclic Aromatic Hydrocarbons in Human Breast Carcinoma MCF-7 Cells Reflects Both Genotoxic and Nongenotoxic Events
ková*,1
ek*,
,1,2
ivoj Vojt
ek

* Department of Chemistry and Toxicology, Veterinary Research Institute, 621 32 Brno, Czech Republic;
Laboratory of Cytokinetics, Institute of Biophysics, 612 65 Brno, Czech Republic; and
Laboratory of Tumor Biology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
Received October 1, 2004; accepted November 15, 2004
Polycyclic aromatic hydrocarbons (PAHs), such as benzo[a]pyrene (BaP), are carcinogens suggested to be involved in development of human cancer. Several recent studies have reported that PAHs can activate estrogen receptors (ER), either directly or indirectly by producing estrogenic metabolites. We hypothesized that the activation of ER by PAHs or their metabolites could induce cell proliferation in estrogen-sensitive cells. In the present study, we found that two PAHs, benz[a]anthracene (BaA) and BaP, can stimulate proliferation of human breast carcinoma MCF-7 cells at concentrations 100 nM and higher. This effect was ER-dependent, because it was blocked by the pure antiestrogen ICI 182,780. Although both PAHs partially inhibited S-phase entry and DNA synthesis induced by 17ß-estradiol, they stimulated S-phase entry when applied to MCF-7 cells synchronized by serum deprivation. This was in contrast with model antiestrogenic aryl hydrocarbon receptor ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin, which fully suppressed S-phase entry. BaP, which is a strong mutagen, was found to induce p53 tumor suppressor expression, a partial S-phase arrest and at higher concentrations also cell death. Pifithrin-
, a synthetic inhibitor of p53 activity, abolished both S-phase arrest and apoptosis induced by genotoxic PAHs, and it potentiated the proliferative effect of BaP. Thus, both genotoxic and nongenotoxic events seem to interact in the effects of BaP on cell proliferation. Taken together, our data indicate that both BaA and BaP can stimulate cell proliferation through activation of ER. The proliferative effects of these carcinogenic compounds might contribute to tumor promotion in estrogen-sensitive tissues.
Key Words: PAHs; estrogen receptor; p53; cell cycle; cell proliferation.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
H. Jiao, S. L. Allinson, M. J. Walsh, R. Hewitt, K. J. Cole, D. H. Phillips, and F. L. Martin Growth kinetics in MCF-7 cells modulate benzo[a]pyrene-induced CYP1A1 up-regulation Mutagenesis, March 1, 2007; 22(2): 111 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Caino, J. L. Oliva, H. Jiang, T. M. Penning, and M. G. Kazanietz Benzo[a]pyrene-7,8-dihydrodiol Promotes Checkpoint Activation and G2/M Arrest in Human Bronchoalveolar Carcinoma H358 Cells Mol. Pharmacol., March 1, 2007; 71(3): 744 - 750. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Sparfel, J. Van Grevenynghe, M. Le Vee, C. Aninat, and O. Fardel Potent inhibition of carcinogen-bioactivating cytochrome P450 1B1 by the p53 inhibitor pifithrin {alpha} Carcinogenesis, March 1, 2006; 27(3): 656 - 663. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. C.M. Staal, M. H.M. van Herwijnen, F. J. van Schooten, and J. H.M. van Delft Modulation of gene expression and DNA adduct formation in HepG2 cells by polycyclic aromatic hydrocarbons with different carcinogenic potencies Carcinogenesis, March 1, 2006; 27(3): 646 - 655. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Abdelrahim, E. Ariazi, K. Kim, S. Khan, R. Barhoumi, R. Burghardt, S. Liu, D. Hill, R. Finnell, B. Wlodarczyk, et al. 3-Methylcholanthrene and Other Aryl Hydrocarbon Receptor Agonists Directly Activate Estrogen Receptor {alpha} Cancer Res., February 15, 2006; 66(4): 2459 - 2467. [Abstract] [Full Text] [PDF] |
||||



